心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

急性冠状动脉综合征非血运重建患者抗血小板治疗中国专家共识（2018）

2019-07-23 中国医师协会心血管内科医师分会 中华心血管病杂志,2019,47(6):430-442.

急性冠状动脉综合征抗血小板治疗

非血运重建是急性冠状动脉综合征(ACS)患者的治疗选择之一，与接受经皮冠状动脉介入治疗(PCI)的患者相比，非血运重建ACS患者不良心血管事件风险更高、预后更差。自2009年我国《急性冠状动脉综合征非血运重建患者抗血小板治疗的中国专家共识》发布以来，近年在该疾病领域积累了较多新的临床证据。该共识结合我国国情及实践，对ACS(包括特殊类型ACS)tE血运重建患者抗血小板治疗提出建议，以期推进我国AC

中文标题：

急性冠状动脉综合征非血运重建患者抗血小板治疗中国专家共识（2018）

发布机构：

中国医师协会心血管内科医师分会

发布日期：

2019-07-23

简要介绍：

非血运重建是急性冠状动脉综合征(ACS)患者的治疗选择之一，与接受经皮冠状动脉介入治疗(PCI)的患者相比，非血运重建ACS患者不良心血管事件风险更高、预后更差。自2009年我国《急性冠状动脉综合征非血运重建患者抗血小板治疗的中国专家共识》发布以来，近年在该疾病领域积累了较多新的临床证据。该共识结合我国国情及实践，对ACS(包括特殊类型ACS)tE血运重建患者抗血小板治疗提出建议，以期推进我国ACS非血运重建患者抗血小板治疗的规范化管理。 

拓展指南：与急性冠脉综合征相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=急性冠状动脉综合征非血运重建患者抗血小板治疗中国专家共识（2018）)] GetToolGuiderByIdResponse(projectId=1, id=b4e2c1c001e73963, title=急性冠状动脉综合征非血运重建患者抗血小板治疗中国专家共识（2018）, enTitle=, guiderFrom=中华心血管病杂志,2019,47(6):430-442., authorId=null, author=, summary=非血运重建是急性冠状动脉综合征(ACS)患者的治疗选择之一，与接受经皮冠状动脉介入治疗(PCI)的患者相比，非血运重建ACS患者不良心血管事件风险更高、预后更差。自2009年我国《急性冠状动脉综合征非血运重建患者抗血小板治疗的中国专家共识》发布以来，近年在该疾病领域积累了较多新的临床证据。该共识结合我国国情及实践，对ACS(包括特殊类型ACS)tE血运重建患者抗血小板治疗提出建议，以期推进我国AC, cover=, journalId=null, articlesId=null, associationId=315, associationName=中国医师协会心血管内科医师分会, associationIntro=null, copyright=0, guiderPublishedTime=Tue Jul 23 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<div>非血运重建是急性冠状动脉综合征(ACS)患者的治疗选择之一，与接受经皮冠状动脉介入治疗(PCI)的患者相比，非血运重建ACS患者不良心血管事件风险更高、预后更差。自2009年我国《急性冠状动脉综合征非血运重建患者抗血小板治疗的中国专家共识》发布以来，近年在该疾病领域积累了较多新的临床证据。该共识结合我国国情及实践，对ACS(包括特殊类型ACS)tE血运重建患者抗血小板治疗提出建议，以期推进我国ACS非血运重建患者抗血小板治疗的规范化管理。 </div> <div><br> </div>拓展指南：<strong>与<font color=red>急性冠脉综合征</font>相关指南：</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=fff041c001ea264b" title="2019 EAPCI专家共识：冠脉腔内影像学检查的临床应用-第2部分：急性冠脉综合征冠脉造影结果模糊患者介入治疗决策指导" target=_blank>2019 EAPCI专家共识：冠脉腔内影像学检查的临床应用-第2部分：急性冠脉综合征冠脉造影结果模糊患者介入治疗决策指导</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=40ed41c001e35370" title="急性冠脉综合征急诊快速诊治指南（2019）" target=_blank>急性冠脉综合征急诊快速诊治指南（2019）</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=f01cc1c001e290f8" title="2018 JCS指南：急性冠脉综合征的诊断和治疗" target=_blank>2018 JCS指南：急性冠脉综合征的诊断和治疗</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=a1be41c001e13236" title="2019 专家建议：延长亚洲急性冠脉综合征患者双抗治疗" target=_blank>2019 专家建议：延长亚洲急性冠脉综合征患者双抗治疗</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=c35121c00162226a" title="2018 欧洲联合共识声明：房颤患者表现为急性冠脉综合征和/或经皮心血管介入治疗的抗栓治疗管理" target=_blank>2018 欧洲联合共识声明：房颤患者表现为急性冠脉综合征和/或经皮心血管介入治疗的抗栓治疗管理</a></li> 更多信息请点击：<a href="https://www.medsci.cn/guideline/list.do?q=%E6%80%A5%E6%80%A7%E5%86%A0%E8%84%89%E7%BB%BC%E5%90%88%E5%BE%81" target=_blank>有关急性冠脉综合征更多指南</a></ul>, tagList=[TagDto(tagId=3430, tagName=急性冠状动脉综合征), TagDto(tagId=2733, tagName=抗血小板治疗)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=38, categoryName=急重症科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6333, appHits=937, showAppHits=48, pcHits=3329, showPcHits=2939, likes=87, shares=50, comments=10, approvalStatus=1, publishedTime=Tue Jul 30 23:17:02 CST 2019, publishedTimeString=2019-07-23, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Tue Jul 30 23:17:02 CST 2019, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 13:43:30 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=急性冠状动脉综合征非血运重建患者抗血小板治疗中国专家共识（2018）)])
急性冠状动脉综合征非血运重建患者抗血小板治疗中国专家共识（2018）
下载请点击：
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2103666, encodeId=225421036664b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35465387413, createdName=ms8000002020716804, createdTime=Thu Dec 01 09:50:51 CST 2022, time=2022-12-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1230787, encodeId=969a1230e87a9, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0b45319731, createdName=148a6a1em09暂无昵称, createdTime=Tue Jul 05 22:15:17 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969704, encodeId=aebb969e0441, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/c4a2f0cf055e4bc8bb3970902a633d4c/150e8482ab7446959f44f9c8dd6e022c.jpg, createdBy=19d75217845, createdName=1477308bm10(暂无昵称), createdTime=Sun May 30 23:09:58 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897435, encodeId=3f0689e4359d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/c4a2f0cf055e4bc8bb3970902a633d4c/150e8482ab7446959f44f9c8dd6e022c.jpg, createdBy=19d75217845, createdName=1477308bm10(暂无昵称), createdTime=Fri Nov 06 22:51:30 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807745, encodeId=a9b280e7453b, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 09:48:21 CST 2020, time=2020-08-12, status=1, ipAttribution=)]
    2022-12-01 ms8000002020716804 来自广东省

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2103666, encodeId=225421036664b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35465387413, createdName=ms8000002020716804, createdTime=Thu Dec 01 09:50:51 CST 2022, time=2022-12-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1230787, encodeId=969a1230e87a9, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0b45319731, createdName=148a6a1em09暂无昵称, createdTime=Tue Jul 05 22:15:17 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969704, encodeId=aebb969e0441, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/c4a2f0cf055e4bc8bb3970902a633d4c/150e8482ab7446959f44f9c8dd6e022c.jpg, createdBy=19d75217845, createdName=1477308bm10(暂无昵称), createdTime=Sun May 30 23:09:58 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897435, encodeId=3f0689e4359d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/c4a2f0cf055e4bc8bb3970902a633d4c/150e8482ab7446959f44f9c8dd6e022c.jpg, createdBy=19d75217845, createdName=1477308bm10(暂无昵称), createdTime=Fri Nov 06 22:51:30 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807745, encodeId=a9b280e7453b, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 09:48:21 CST 2020, time=2020-08-12, status=1, ipAttribution=)]
    2022-07-05 148a6a1em09暂无昵称

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2103666, encodeId=225421036664b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35465387413, createdName=ms8000002020716804, createdTime=Thu Dec 01 09:50:51 CST 2022, time=2022-12-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1230787, encodeId=969a1230e87a9, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0b45319731, createdName=148a6a1em09暂无昵称, createdTime=Tue Jul 05 22:15:17 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969704, encodeId=aebb969e0441, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/c4a2f0cf055e4bc8bb3970902a633d4c/150e8482ab7446959f44f9c8dd6e022c.jpg, createdBy=19d75217845, createdName=1477308bm10(暂无昵称), createdTime=Sun May 30 23:09:58 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897435, encodeId=3f0689e4359d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/c4a2f0cf055e4bc8bb3970902a633d4c/150e8482ab7446959f44f9c8dd6e022c.jpg, createdBy=19d75217845, createdName=1477308bm10(暂无昵称), createdTime=Fri Nov 06 22:51:30 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807745, encodeId=a9b280e7453b, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 09:48:21 CST 2020, time=2020-08-12, status=1, ipAttribution=)]
    2021-05-30 1477308bm10(暂无昵称)

    学习好资料

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2103666, encodeId=225421036664b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35465387413, createdName=ms8000002020716804, createdTime=Thu Dec 01 09:50:51 CST 2022, time=2022-12-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1230787, encodeId=969a1230e87a9, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0b45319731, createdName=148a6a1em09暂无昵称, createdTime=Tue Jul 05 22:15:17 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969704, encodeId=aebb969e0441, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/c4a2f0cf055e4bc8bb3970902a633d4c/150e8482ab7446959f44f9c8dd6e022c.jpg, createdBy=19d75217845, createdName=1477308bm10(暂无昵称), createdTime=Sun May 30 23:09:58 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897435, encodeId=3f0689e4359d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/c4a2f0cf055e4bc8bb3970902a633d4c/150e8482ab7446959f44f9c8dd6e022c.jpg, createdBy=19d75217845, createdName=1477308bm10(暂无昵称), createdTime=Fri Nov 06 22:51:30 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807745, encodeId=a9b280e7453b, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 09:48:21 CST 2020, time=2020-08-12, status=1, ipAttribution=)]
    2020-11-06 1477308bm10(暂无昵称)

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2103666, encodeId=225421036664b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35465387413, createdName=ms8000002020716804, createdTime=Thu Dec 01 09:50:51 CST 2022, time=2022-12-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1230787, encodeId=969a1230e87a9, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0b45319731, createdName=148a6a1em09暂无昵称, createdTime=Tue Jul 05 22:15:17 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969704, encodeId=aebb969e0441, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/c4a2f0cf055e4bc8bb3970902a633d4c/150e8482ab7446959f44f9c8dd6e022c.jpg, createdBy=19d75217845, createdName=1477308bm10(暂无昵称), createdTime=Sun May 30 23:09:58 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897435, encodeId=3f0689e4359d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/c4a2f0cf055e4bc8bb3970902a633d4c/150e8482ab7446959f44f9c8dd6e022c.jpg, createdBy=19d75217845, createdName=1477308bm10(暂无昵称), createdTime=Fri Nov 06 22:51:30 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807745, encodeId=a9b280e7453b, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4bd5125128, createdName=14643f34m67暂无昵称, createdTime=Wed Aug 12 09:48:21 CST 2020, time=2020-08-12, status=1, ipAttribution=)]
    2020-08-12 14643f34m67暂无昵称

    学习好资料

    0

相关指南

急性冠状动脉综合征患者早期抗栓治疗及院间转运专家共识

中国心血管相关专家小组（统称） · 2019-06-01

高龄老年（≥75 岁）急性冠状动脉综合征患者规范化诊疗中国专家共识

中国老年学和老年医学学会(CAGG,China Association of Gerontology and Geriatrics) 心脑血管病专业委员会 · 2018-09-20

急性冠状动脉综合征特殊人群抗血小板治疗中国专家建议

中国医师协会心血管内科医师分会(CCCP,Chinese College of Cardiovascular Physicians) · 2018-04-30

2016 急性冠状动脉综合征抗栓治疗合并出血防治多学科专家共识

中国医师协会心血管内科医师分会(CCCP,Chinese College of Cardiovascular Physicians) · 2016-10-25

2016 基层医院急性冠状动脉综合征临床诊疗中心肌肌钙蛋白检测应用专家共识

中国心血管病相关专家小组（统称） · 2016-10-15

2015 中国急诊急性冠状动脉综合征临床实践指南(二)——诊断篇

中国医师协会急诊医师分会(CHINESE COLLEGE OF EMERGENCY PHYSICANS,CCEP) · 2016-01-30